News
Shares of Hims & Hers Health Inc. have roughly doubled over the past year — and Chief Executive Andrew Dudum cashed in on the ...
Novo Nordisk's legal actions against U.S. pharmacies over compounded copies of its drug Wegovy exclude Hims & Hers, a ...
Hims & Hers is a top telehealth stock with strong revenue growth, innovative offerings, and long-term potential. Click here ...
Danish drugmaker Novo Nordisk said on Tuesday it has filed 14 new lawsuits in the United States against the sale of ...
3don MSN
Hims & Hers Shares Plunge. Is This a Buying Opportunity or Should Investors Run for the Hills?
Hims & Hers continues to spend heavily on marketing to attract new customers. During the quarter, its marketing spending jumped 50% to nearly $218 million. Marketing expenses took up 40% of revenue in ...
Hims & Hers Health ( NYSE: HIMS) shares traded lower for the second straight session on Tuesday after the telehealth firm’s ...
Danish leader will face a challenging landscape among competitors ...
Hims & Hers has been an incredible stock to own over the last few years, making shareholders rich. It has $2 billion in ...
On April 29, 2025, Hims & Hers and Novo Nordisk unveiled a landmark collaboration to bring Wegovy—Novo's blockbuster ...
Novo Nordisk is ending a partnership with Hims & Hers. The fallout comes over claims the telehealth platform sold copycat versions of the pharmaceutical giant’s weight-loss drug Wegovy.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback